Flecainide

• Description :

  Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2) . Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) [1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Potassium Channel; Sodium Channel

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/flecainide.html

• Purity :

  99.98

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=CC(OCC(F)(F)F)=CC=C1OCC(F)(F)F)NCC2NCCCC2

• Molecular Formula :

  C17H20F6N2O3

• Molecular Weight :

  414.34

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Watanabe H, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009 Apr;15 (4) :380-3. |[2]Kuroda Y, et al. Flecainide ameliorates arrhythmogenicity through NCX flux in Andersen-Tawil syndrome-iPS cell-derived cardiomyocytes. Biochem Biophys Rep. 2017 Jan 11;9:245-256.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [54143-55-4]